CVRX - NASDAQ
CVRx, Inc.
$5.39
-1.3%CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
At a Glance
Live Snapshotcvrx
Selling, General and Administrative Expenses
Last Annual Value
88.47M
3-Year CAGR
21%
5-Year CAGR
56%
10-Year CAGR
31%
CVRx, Inc. Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
CVRx, Inc. NASDAQ:CVRX | 88.47M | 11.1% | 26.0% | N/A | |
 908 Devices Inc. NASDAQ:MASS | 38.53M | N/A | 3.6% | N/A | |
 Foghorn Therapeutics Inc. NASDAQ:FHTX | 27.55M | -5.2% | 4.9% | N/A | |
 Inogen, Inc. NASDAQ:INGN | 165.07M | -3.3% | 1.8% | 9.1% | |
 Lifecore Biomedical, Inc. NASDAQ:LFCR | 44.05M | 4.2% | 9.7% | -1.2% | |
 Outset Medical, Inc. NASDAQ:OM | 92.22M | -13.3% | -1.9% | N/A | |
 OraSure Technologies, Inc. NASDAQ:OSUR | 73.79M | -7.1% | -4.9% | 2.4% | |
 Sight Sciences, Inc. NASDAQ:SGHT | 89.16M | -6.4% | 3.2% | N/A | |
 SANUWAVE Health, Inc. NASDAQ:SNWV | 26.79M | 25.4% | 5.7% | 25.9% | |
 Viemed Healthcare, Inc. NASDAQ:VMD | 121.37M | 9.0% | 15.1% | 24.3% | |
 Cerus Corporation NASDAQ:CERS | 80.91M | 2.3% | -0.1% | 5.2% |
CVRx, Inc. Fair Value Envelope
Related Guides
Continue your CVRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.